Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeted degradation of the enhancer lysine acetyltransferases CBP and p300
Raghu Vannam, Jan Fehmi Sayılgan, Samuel Ojeda, et al.
Cell chemical biology (2021) Vol. 28, Iss. 4, pp. 503-514.e12
Open Access | Times Cited: 124

Showing 1-25 of 124 citing articles:

Proteolysis-targeting chimeras (PROTACs) in cancer therapy
Xinyi Li, Wenchen Pu, Qingquan Zheng, et al.
Molecular Cancer (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 187
Targeted protein degradation: A promise for undruggable proteins
Kusal T. G. Samarasinghe, Craig M. Crews
Cell chemical biology (2021) Vol. 28, Iss. 7, pp. 934-951
Open Access | Times Cited: 186
PROTACs: great opportunities for academia and industry (an update from 2020 to 2021)
Ming He, Chao-Guo Cao, Zhihao Ni, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 168
Chemistries of bifunctional PROTAC degraders
Chao-Guo Cao, Ming He, Liguo Wang, et al.
Chemical Society Reviews (2022) Vol. 51, Iss. 16, pp. 7066-7114
Closed Access | Times Cited: 168
Unraveling the Role of Linker Design in Proteolysis Targeting Chimeras
Troy A. Bemis, James J. La Clair, Michael D. Burkart
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 12, pp. 8042-8052
Closed Access | Times Cited: 152
EP300 Selectively Controls the Enhancer Landscape of MYCN-Amplified Neuroblastoma
Adam D. Durbin, Tingjian Wang, Virangika K. Wimalasena, et al.
Cancer Discovery (2021) Vol. 12, Iss. 3, pp. 730-751
Open Access | Times Cited: 111
Identification and functional characterization of transcriptional activators in human cells
Nader Alerasool, He Leng, Zhen‐Yuan Lin, et al.
Molecular Cell (2022) Vol. 82, Iss. 3, pp. 677-695.e7
Open Access | Times Cited: 103
Strategies for designing proteolysis targeting chimaeras (PROTACs)
Shipeng He, Guoqiang Dong, Junfei Cheng, et al.
Medicinal Research Reviews (2022) Vol. 42, Iss. 3, pp. 1280-1342
Closed Access | Times Cited: 73
The Role of CREBBP/EP300 and Its Therapeutic Implications in Hematological Malignancies
Yu Zhu, Zi Wang, Yanan Li, et al.
Cancers (2023) Vol. 15, Iss. 4, pp. 1219-1219
Open Access | Times Cited: 50
Advancing Strategies for Proteolysis-Targeting Chimera Design
Minglei Li, Ying Zhi, Bo Liu, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 4, pp. 2308-2329
Closed Access | Times Cited: 46
Epigenetics-targeted drugs: current paradigms and future challenges
Wanlin Dai, Xinbo Qiao, Yuanyuan Fang, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 24
Histone lysine acetyltransferase inhibitors: an emerging class of drugs for cancer therapy
Jeffrey D. White, Frederick A. Derheimer, Kristen Jensen-Pergakes, et al.
Trends in Pharmacological Sciences (2024) Vol. 45, Iss. 3, pp. 243-254
Open Access | Times Cited: 19
Pharmacological targeting of the cancer epigenome
Nathaniel W. Mabe, Jennifer A. Perry, Clare F. Malone, et al.
Nature Cancer (2024) Vol. 5, Iss. 6, pp. 844-865
Closed Access | Times Cited: 19
A rapid chemical reprogramming system to generate human pluripotent stem cells
Yanglu Wang, Fangqi Peng, Zhihan Yang, et al.
Nature Chemical Biology (2025)
Closed Access | Times Cited: 5
Expanding the arsenal of E3 ubiquitin ligases for proximity-induced protein degradation
Aimo Kannt, Ivan Đikić
Cell chemical biology (2021) Vol. 28, Iss. 7, pp. 1014-1031
Open Access | Times Cited: 100
Developments of CRBN-based PROTACs as potential therapeutic agents
Chao Wang, Yujing Zhang, Yudong Wu, et al.
European Journal of Medicinal Chemistry (2021) Vol. 225, pp. 113749-113749
Closed Access | Times Cited: 96
Single-cell and bulk transcriptomics of the liver reveals potential targets of NASH with fibrosis
Zhongyi Wang, Adrian Keogh, Annick Waldt, et al.
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 77
CBP/p300: Critical Co-Activators for Nuclear Steroid Hormone Receptors and Emerging Therapeutic Targets in Prostate and Breast Cancers
Aaron Waddell, Haojie Huang, Daiqing Liao
Cancers (2021) Vol. 13, Iss. 12, pp. 2872-2872
Open Access | Times Cited: 72
Peptide-based PROTAC degrader of FOXM1 suppresses cancer and decreases GLUT1 and PD-L1 expression
Kun Wang, Xiaoyong Dai, Albert Cheung Hoi Yu, et al.
Journal of Experimental & Clinical Cancer Research (2022) Vol. 41, Iss. 1
Open Access | Times Cited: 54
Discovery of Exceptionally Potent, Selective, and Efficacious PROTAC Degraders of CBP and p300 Proteins
J. Thomas, Mi Wang, Wei Jiang, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 12, pp. 8178-8199
Closed Access | Times Cited: 33
BRD4-targeting PROTAC as a unique tool to study biomolecular condensates
Yi Shi, Yuan Liao, Qianlong Liu, et al.
Cell Discovery (2023) Vol. 9, Iss. 1
Open Access | Times Cited: 28
Discovery of CBPD-268 as an Exceptionally Potent and Orally Efficacious CBP/p300 PROTAC Degrader Capable of Achieving Tumor Regression
Zhixiang Chen, Mi Wang, Dimin Wu, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 7, pp. 5275-5304
Closed Access | Times Cited: 15
Discovery of Novel PROTAC Degraders of p300/CBP as Potential Therapeutics for Hepatocellular Carcinoma
Qi Chang, Jiayi Li, Yue Deng, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 4, pp. 2466-2486
Closed Access | Times Cited: 14
Tumor-targeted PROTAC prodrug nanoplatform enables precise protein degradation and combination cancer therapy
Zhifeng Zou, Lei Yang, Hui-Jun Nie, et al.
Acta Pharmacologica Sinica (2024) Vol. 45, Iss. 8, pp. 1740-1751
Closed Access | Times Cited: 14
Discovery of CBPD-409 as a Highly Potent, Selective, and Orally Efficacious CBP/p300 PROTAC Degrader for the Treatment of Advanced Prostate Cancer
Zhixiang Chen, Mi Wang, Dimin Wu, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 7, pp. 5351-5372
Closed Access | Times Cited: 12
Page 1 - Next Page

Scroll to top